Skip to main content
Cancer Science logoLink to Cancer Science
. 2021 May 2;112(5):2063. doi: 10.1111/cas.14893

Correction

PMCID: PMC8088966  PMID: 33934430

In an article 1 titled “Benefit‐risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers” by Di Bei, Mayu Osawa, Shinji Uemura, Tomoya Ohno, Jogarao Gobburu, Amit Roy, Mayumi Hasegawa, the authors would like to correct the description under section 2.4 in Materials and Methods.

The sentence “E‐R models of OS and ORR that included 1749 and 1710 patients, respectively, now included 134 Japanese patients from regional studies.” should read as “E‐R models of OS and ORR that included 1749 patients, now included 134 Japanese patients from regional studies.”

The authors apologize for the error.

REFERENCE

  • 1. Bei DI, Osawa M, Uemura S, et al. Benefit‐risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers. Cancer Sci. 2020;111:528‐535. 10.1111/cas.14252 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES